Paul Swiecicki

33PUBLICATIONS
201CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Disease surveillancePharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Sep 15, 2026
Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study.

|Jun 18, 2026
Late Recurrences Beyond Five Years in Salivary Adenoid Cystic Carcinoma: Implications for Long-Term Surveillance.

|May 31, 2026
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

|May 05, 2026
Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.

|Mar 27, 2026
Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609).

Paul L Swiecicki, Megan Othus, Sandip P Patel

|Mar 20, 2026
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.

Alexander T Pearson, Jameel Muzaffar, Kedar Kirtane

Pageof 6

Frequent Collaborators

6 joint publications

Matthew E Spector

6 joint publications

Ari Joseph Rosenberg

6 joint publications

Mark Prince

6 joint publications

J Chad Brenner